On October 28th-29th 2025, Euro-ataxia hosted the International Patient Conference in Amsterdam. This two-day event was attended by representatives from 18 ataxia patient organisations from Europe and North America. We were also joined by representatives from six pharmaceutical companies, and a number of ataxia researchers. We heard updates on clinical programmes on a range of […]
Reflections on the 2025 Euro-ataxia conference Read More »
The pharmaceutical company Lexeo Therapeutics has announced positive updates from their phase I/II trial of the gene therapy LX2006 to treat cardiomyopathy in Friedreich’s ataxia (FA). Interim data has shown sustained or deepening improvements in most participants across both cardiac and neurological measures of FA. This includes clinically meaningful improvement in the modified Friedreich Ataxia
Lexeo shares positive data in trial of LX2006 for FA cardiomyopathy Read More »
On 7th and 8th May, Ataxia UK’s Research Communications Officer, Scarlett Parr-Reid, attended Beacon for Rare Diseases and Remedi4All’s second International Drug Repurposing Conference (IDR25), held in Amsterdam. Drug repurposing involves finding new therapeutic uses for drugs that are already approved for use in other conditions. One example of this which was showcased at IDR25
Reflections from the International Drug Repurposing Conference 2025 Read More »
Ataxia UK has worked closely with researches at the London Ataxia Centre and other experts on a research study assessing the impact of specialist ataxia centres (SACs) in Europe. This was part of the Value of Treatment (VoT) project supported by the European Brain Council, a non-profit organisation which promotes brain research to improve the
About the PROSPAX project The PROSPAX consortium of patient groups, researchers and clinicians across Europe and Canada (including the UK), set up the PROSPAX project to study the progression of spastic ataxias over time, in a rigorous and harmonised way – from the clinical to the molecular level. This has included clinical, imaging, digital-motor and
The International Congress for Ataxia Research (ICAR) 2024 took place in London from 12th – 15th November. It was organised by Ataxia UK, the National Ataxia Foundation, the Friedreich’s Ataxia Research Alliance, and the Ataxia Global Initiative. This was the biggest ICAR yet, with 600 in-person attendees and 50 attending online from 32 countries, including researchers,
Highlights of the International Congress for Ataxia Research 2024 Read More »
The 2024 Euro-ataxia conference took place in London on 15th-16th November, organised by Ataxia UK. The conference was a great success; fourteen ataxia patient groups, as well as researchers and pharmaceutical representatives gathered to share best practice in healthcare and research. Talks included updates from clinical trials, patient group presentations, and panel discussions. On the
Ataxia patient organisations united at the 2024 Euro-ataxia annual conference Read More »
On September 23rd, 2024, the pharmaceutical company Biohaven announced positive topline results from their study of the drug Troriluzole to treat SCAs 1,2,3,6,7,8 and 10. Those with SCA who were treated with Troriluzole showed a 50 – 70% slowing of disease progression, compared to those with SCA who were untreated over a 3-year study
Ataxia UK has worked closely with the London Ataxia Centre researchers and other experts on a research study assessing the impact of specialist ataxia centres in Europe. This was part of the Value of Treatment (VoT) project supported by the European Brain Council, a non-profit organisation which promotes brain research to improve the lives of
The PROSPAX (PROgression chart of SPAstic ataXias) project focuses on ARSACS and SPG7, and is a collaboration between neurologists in several sites across Europe and Canada. The overall aim is to gain a better understanding of how spastic ataxias progress over time to prepare well-designed treatment trials for these conditions, that will be applicable to many of the >100 other
